Skip to content

Clinical study on the combination of Chinese medicine and acupuncture point embedding based on the "meridian-neuro-endocrine immune" system in the treatment of psoriasis with liver depression

Clinical study on the combination of Chinese medicine and acupuncture point embedding based on the "meridian-neuro-endocrine immune" system in the treatment of psoriasis with liver depression

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400081041
Enrollment
Unknown
Registered
2024-02-21
Start date
2022-03-26
Completion date
Unknown
Last updated
2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

Treatment group:Topical CalcipotriolOral DANZHIXIAOYAO PillsAcupuncture Point Embedding Treatment
Control group:Topical CalcipotriolOral DANZHIXIAOYAO Pills

Sponsors

Shaanxi Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Meets the diagnostic criteria for common psoriasis with a BSA = 10%; the TCM classification conforms to the TCM liver-depression syndrome; 2.Both sexes, 18 years = age = 70 years; 3.No use of corticosteroids, immunosuppressants or other related drugs in the last 1 month; 4.The subject or guardian has signed an informed consent form; 5.Pre-treatment blood and urine tests, liver and kidney function and electrocardiogram were all within normal limits.

Exclusion criteria

Exclusion criteria: 1.Patients who have received systemic therapy (Avelox, glucocorticoids, immunosuppressive and anti-inflammatory drugs, etc.) or phototherapy (UVB, PUVA) within 1 month prior to the trial; 2.Patients with the phenomenon of anaphylaxis; 3.Women who are pregnant or breastfeeding; 4.Persons known to be allergic to any of the ingredients in DANZHIXIAOYAO Pills,Absorbable surgical sutures or Calcipotriol; 5.Needle-sick person and those who cannot tolerate buried threads in acupuncture points; 6.Those who are participating or have participated in other research projects within the last 1 month; 7.Patients with severe primary diseases of the combined cardiovascular, cerebrovascular, hepatic, renal and haematopoietic systems and psychiatric disorders; 8.Patients who refuse to sign the informed consent form, or who are estimated to have poor compliance and poor follow-up possibilities.

Design outcomes

Primary

MeasureTime frame
Psoriasis Area and Severity Index;Skin lesion body surface area score;Adrenocorticotropin-releasing hormone;Opioid melanopsin-promoting corticotropinogen;Alpha-melanocyte stimulating hormone;Interleukin-1;Interleukin-6;Interleukin-10;

Secondary

MeasureTime frame
Physician Subjective Assessment Index;Dermatology Quality of Life Index;Anxiety Self-Assessment Scale scores;Depression Self-Rating Scale scores;Self-evaluation of itching symptoms;Chinese Medicine Evidence Score;

Countries

China

Contacts

Public ContactCHEN LU

Shaanxi Provincial Hospital of Traditional Chinese Medicine

402087151@qq.com+86 180 6682 3131

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026